Accellix, Inc. and Streck Collaborate to Advance Cell Therapy with Quality Control
24.9.2025 14:00:00 CEST | Business Wire | Press release
Accellix™, a pioneer in automated flow cytometry, and Streck, a recognized leader in quality control materials for flow cytometry, hematology and molecular diagnostics, have announced a strategic collaboration with the addition of the Accellix Automated Cell Phenotyping Platform to Streck’s CD-Chex Plus® (RUO) control.
The Accellix platform is a compact, fully automated flow cytometer designed for point-of-need environments. It uses single-use, microfluidic cartridges to automate the entire cell phenotyping process, from antibody staining to flow cytometry acquisition and data analysis. This enables rapid, reproducible results without the need for complex instrumentation or specialized operators.
By integrating CD-Chex Plus (RUO) control into the Accellix workflow, users can assess the Accellix platform performance and ensure reliable operation. This addition supports routine monitoring and helps users maintain trust in their data without introducing complexity or requiring a separate or centralized lab infrastructure.
“This collaboration reflects our commitment to helping cell therapy developers and labs worldwide achieve faster, more reliable results. By aligning with Streck and CD-Chex Plus (RUO) control, we’re making it easier to simplify flow cytometry quality control across a multitude of instruments, locations and environments utilizing the Accellix technology,” said Rey Mali, Chief Operations Officer at Accellix.
“We’re excited to work with a team that shares our mission to support laboratories and companies with reliable, streamlined solutions that enable positive outcomes in health care,” said Matt Thummel, Director of Business Segment – Hematology, Body Fluids and Flow Cytometry at Streck. “Adding the Accellix platform to the CD-Chex Plus (RUO) control gives platform users a dependable way to monitor performance and maintain confidence in their results, especially in fast-paced manufacturing environments.”
The Accellix Automated Cell Phenotyping Platform will be added to the CD-Chex Plus (RUO) control with lot 5265, shipping September 22, 2025.
CD-Chex Plus (RUO) is For Research Use Only. Not for use in diagnostic procedures.
About Accellix, Inc.
Accellix is a biotechnology company dedicated to developing and commercializing the Accellix Platform to enable its customers in the fields of cell and gene therapy and blood characterization to meet their critical QC requirements as they advance life-changing therapies benefiting patients worldwide. Accellix empowers its customers by migrating their existing cell phenotyping assays to the Accellix Platform. The Accellix Platform is a benchtop cytometer operating and reading capillary cartridges integrated with dry reagents. It provides unmatched reproducibility and ease of use for automated multi-parametric cell analysis. For more information, visit www.accellix.com.
About Streck, Inc.
Established in 1971, Streck provides solutions that ensure every result counts by empowering clinical and research laboratories to reliably deliver accurate results, advance diagnostics and enable healthier, happier lives for patients everywhere. Streck products are manufactured in La Vista, Nebraska, and delivered to thousands of labs worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250924981154/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Iconic Landmark Danjiang Bridge Opened to Redefine Taiwan18.5.2026 12:02:00 CEST | Press release
The Danjiang Bridge, one of Taiwan’s most significant recent public infrastructure projects, officially opened with a series of large-scale public events, transforming the bridge into a new cultural landmark and civic space. The program featured the “Danjiang Bridge Together Arts Festival,” immersive public activities, and a special performance of Light Chain by Cloud Gate Dance Theatre, symbolizing the integration of architecture, engineering, and the arts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517667930/en/ The Danjiang Bridge is an iconic landmark in Taiwan with global recognition. (Photo via Highway Bureau , Motc) Spanning the mouth of the Tamsui River, the bridge serves as both a major transportation project and a recognizable architectural landmark, establishing a new urban symbol for Taiwan. Designed by Zaha Hadid Architects, the project gained international attention throughout its development and was sel
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 09:00:00 CEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 09:00:00 CEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 09:00:00 CEST | Press release
Expanded availability of LogicMonitor within Deutsche Telekom’s managed services portfolio follows successful operational use in the UKSelect outcomes include reduced reporting times and proactive incident preventionExpansion extends across DACH, Benelux, and the Nordics LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Throug
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 09:00:00 CEST | Press release
ZH9 is very well tolerated with a favourable safety profile, and no dose-limiting toxicities or Grade ≥3 drug-related adverse events reported.ZH9 demonstrates 91% freedom-from-relapse in NMIBC patients who have reached study end.Company plans to run a larger phase 2 study across a range of patient populations spanning intermediate risk and high risk including CIS. Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom